Knudsen F U, Vestermark S
Arch Dis Child. 1978 Aug;53(8):660-3. doi: 10.1136/adc.53.8.660.
After their first episode of febrile convulsions, 195 previously healthy children, aged 6--30 months, were given either diazepam or phenobarbitone for a year. Each child was assigned at random to one of the two medications: children admitted on even days were given a suppository containing 5 mg diazepam every 8 hours when the rectal temperature was greater than or equal to 38.5 degree C. Children admitted on odd days were given treatment with phenobarbitone, 3.5 +/- 1 mg/kg per day. 156 children completed treatment and outpatient control for a year, 83 in the diazepam and 73 in the phenobarbitone group. The rate of recurrence was independent of the prophylactic and 15--16 % of the children in both groups had new febrile convulsions within a year. The recurrence rate after 6 months was also similar, 11% in the diazepam group and 9% in the phenobarbitone group. New convulsions were of similar duration and severity in both groups. In both groups 6% of all febrile episodes led to new convulsions. Long-term treatment with phenobarbitone thus offered no advantage over intermittent diazepam.
195名年龄在6至30个月的健康儿童首次出现热性惊厥后,接受了为期一年的地西泮或苯巴比妥治疗。每个孩子被随机分配到两种药物中的一种:偶数日入院的孩子,当直肠温度大于或等于38.5摄氏度时,每8小时给予一次含5毫克地西泮的栓剂。奇数日入院的孩子则接受苯巴比妥治疗,每天3.5±1毫克/千克。156名儿童完成了为期一年的治疗和门诊随访,地西泮组83名,苯巴比妥组73名。复发率与预防用药无关,两组中15%至16%的儿童在一年内出现了新的热性惊厥。6个月后的复发率也相似,地西泮组为11%,苯巴比妥组为9%。两组中新惊厥的持续时间和严重程度相似。两组中所有发热发作的6%导致了新的惊厥。因此,苯巴比妥长期治疗相对于间歇性地西泮并无优势。